公开(公告)号：WO2018039647A1

公开(公告)日：2018-03-01

申请号：PCT/US2017/048757

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： OLLMANN, Michael ,  LI, Yang ,  ZHANG, Jun ,  BISWAS, Kaustav ,  HOMANN, Oliver ,  MIRANDA, Leslie P. ,  MURRAY, Justin K. ,  WU, Bin ,  YOON, Oh Kyu ,  ALLEN, John Gordon ,  NETIROJJANAKUL, Chawita ,  CHENG, Yuan

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

Abstract translation: 本发明涉及用于减少ASGR1基因表达的RNAi构建体。 还描述了使用这种RNAi构建体来治疗或预防心血管疾病（例如冠状动脉疾病和心肌梗塞）并降低血清非HDL胆固醇水平的方法。

公开(公告)号：WO2020023268A1

公开(公告)日：2020-01-30

申请号：PCT/US2019/042234

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： YU, Xin ,  OUYANG, Wenjun ,  LI, Chi-Ming Kevin ,  EGEN, Jackson Graeme ,  YOON, Oh Kyu ,  DRIVER, Ian Halsey ,  TAKENAKA, Shunsuke ,  THOMSON, Christy Ann ,  WANG, Hongyu

IPC: C07K16/28 ,  A61K39/395

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.